NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

exwannabe,

I think the EAP was discussed by NWBO indirectly by stating the costs involved for restart being prohibitive and, at the point they were at, unnecessary. As for the difference between your option A and B, in option A FDA knows they are randomizing into a trial where there may have been a clear difference seen. By assigning these patients to other options including other trials they have no sure way of knowing thus solving the ethical dilema. Best wishes.